RATIO-SALBUTAMOL SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

SALBUTAMOL (SALBUTAMOL SULFATE)

Beszerezhető a:

TEVA CANADA LIMITED

ATC-kód:

R03AC02

INN (nemzetközi neve):

SALBUTAMOL

Adagolás:

0.5MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

SALBUTAMOL (SALBUTAMOL SULFATE) 0.5MG

Az alkalmazás módja:

INHALATION

db csomag:

2.5ML

Recept típusa:

Prescription

Terápiás terület:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0108887009; AHFS:

Engedélyezési státusz:

CANCELLED POST MARKET

Engedély dátuma:

2019-07-09

Termékjellemzők

PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate nebules P.F. 1.25MG/2.5 ML, 5.0 MG/2.5 ML AMPOULES
Bronchodilator
(beta
2
-adrenergic stimulant)
TEVA CANADA LIMITED..
30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA, M1B 2K9
Control: 165512
DATE OF PREPARATION:
JULY 3, 2013
Teva Canada Limited.
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
7
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................